| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ismael Olmos, Manuel Ibarra, Marta Vázquez, Cecilia Maldonado, Pietro Fagiolino, Gustavo Giachett. Population Pharmacokinetics of Clozapine and Norclozapine and Switchability Assessment between Brands in Uruguayan Patients with Schizophrenia. BioMed research international. vol 2019. 2019-07-22. PMID:30956977. |
clozapine (czp) is an atypical antipsychotic agent commonly used in the treatment of schizophrenia. |
2019-07-22 |
2023-08-13 |
Not clear |
| Wei Wang, Mengru Bai, Ting Jiang, Cui Li, Ping Li, Hui Zhou, Zemin Wang, Liping Li, Huidi Jian. Clozapine-induced reduction of l-carnitine reabsorption via inhibition/down-regulation of renal carnitine/organic cation transporter 2 contributes to liver lipid metabolic disorder in mice. Toxicology and applied pharmacology. vol 363. 2019-07-18. PMID:30465787. |
clozapine, an atypical antipsychotic drug, is widely utilized for the treatment of schizophrenia; however, clozapine-induced metabolic disorders, such as fatty liver and weight gain, warrant increased attention. |
2019-07-18 |
2023-08-13 |
mouse |
| Jibran Y Khokhar, Angela M Henricks, Emily D K Sullivan, Alan I Gree. Unique Effects of Clozapine: A Pharmacological Perspective. Advances in pharmacology (San Diego, Calif.). vol 82. 2019-07-17. PMID:29413518. |
clozapine, the first atypical antipsychotic, is a highly effective medication for patients with schizophrenia who do not respond to other antipsychotics. |
2019-07-17 |
2023-08-13 |
Not clear |
| Jibran Y Khokhar, Angela M Henricks, Emily D K Sullivan, Alan I Gree. Unique Effects of Clozapine: A Pharmacological Perspective. Advances in pharmacology (San Diego, Calif.). vol 82. 2019-07-17. PMID:29413518. |
in addition to its effects in treatment-resistant schizophrenia, clozapine has been shown to decrease suicidality, which occurs at an increased rate in patients with schizophrenia. |
2019-07-17 |
2023-08-13 |
Not clear |
| Jibran Y Khokhar, Angela M Henricks, Emily D K Sullivan, Alan I Gree. Unique Effects of Clozapine: A Pharmacological Perspective. Advances in pharmacology (San Diego, Calif.). vol 82. 2019-07-17. PMID:29413518. |
still preliminary, but consistent data, also suggest that clozapine limits substance use in these patients, an important effect since substance use disorders are common in patients with schizophrenia and are associated with a poor outcome, including an increased risk for suicide and poor response to treatment. |
2019-07-17 |
2023-08-13 |
Not clear |
| David Dickens, Steffen Rädisch, George N Chiduza, Athina Giannoudis, Michael J Cross, Hassan Malik, Elke Schaeffeler, Rowena L Sison-Young, Emma L Wilkinson, Christopher E Goldring, Matthias Schwab, Munir Pirmohamed, Anne T Nie. Cellular Uptake of the Atypical Antipsychotic Clozapine Is a Carrier-Mediated Process. Molecular pharmaceutics. vol 15. issue 8. 2019-07-16. PMID:29944835. |
the weak base antipsychotic clozapine is the most effective medication for treating refractory schizophrenia. |
2019-07-16 |
2023-08-13 |
human |
| Paul J Harriso. D-Amino Acid Oxidase Inhibition: A New Glutamate Twist for Clozapine Augmentation in Schizophrenia? Biological psychiatry. vol 84. issue 6. 2019-06-19. PMID:30165950. |
d-amino acid oxidase inhibition: a new glutamate twist for clozapine augmentation in schizophrenia? |
2019-06-19 |
2023-08-13 |
Not clear |
| Jianmeng Song, Carol Borlido, Vincenzo De Luca, Leah Burton, Gary Remingto. Patient versus rater evaluation of symptom severity in treatment resistant schizophrenia receiving clozapine. Psychiatry research. vol 274. 2019-06-13. PMID:30852435. |
patient versus rater evaluation of symptom severity in treatment resistant schizophrenia receiving clozapine. |
2019-06-13 |
2023-08-13 |
Not clear |
| A Zarina Kraal, Kristen M Ward, Vicki L Ellingro. Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders. Psychopharmacology bulletin. vol 47. issue 2. 2019-05-30. PMID:28626268. |
these results suggest that female schizophrenia patients taking clozapine or olanzapine represent a group at uniquely high risk for metabolic dysfunction and future adverse cardiovascular outcomes, and warrant close monitoring by clinicians to prevent worsening of metabolic risk through proper monitoring and interventions. |
2019-05-30 |
2023-08-13 |
human |
| Ruth Rayikanti, Iga Lentowicz, Badari Birur, Li L. Combined Antipsychotics and Electroconvulsive Therapy in an Acutely Psychotic Patient with Treatment-resistant Schizophrenia. Psychopharmacology bulletin. vol 47. issue 2. 2019-05-30. PMID:28626273. |
treatment of patients with treatment-resistant schizophrenia (trs), who fail to respond to multiple antipsychotic trials, including clozapine (clz), is challenging. |
2019-05-30 |
2023-08-13 |
Not clear |
| Zoltán Rihmer, Attila Németh, Tamás Kurimay, Dóra Perczel-Forintos, György Purebl, Péter Döm. [Recognition, care and prevention of suicidal behaviour in adults]. Psychiatria Hungarica : A Magyar Pszichiatriai Tarsasag tudomanyos folyoirata. vol 32. issue 1. 2019-05-23. PMID:28424378. |
treatment with clozapine is effective in reducing suicidal behaviour in patients with schizophrenia. |
2019-05-23 |
2023-08-13 |
Not clear |
| Hélène Verdoux, Clélia Quiles, Christian J Bachmann, Dan Siskin. Prescriber and institutional barriers and facilitators of clozapine use: A systematic review. Schizophrenia research. vol 201. 2019-05-20. PMID:29880453. |
as clozapine is under-prescribed in persons with treatment-resistant schizophrenia (trs), it is necessary to better identify the determinants of health inequalities in access to clozapine use. |
2019-05-20 |
2023-08-13 |
Not clear |
| Jose M Rubio, Christoph U Correl. Clozapine and long-acting injectable antipsychotics reduce hospitalisation and treatment failure risk in patients with schizophrenia. Evidence-based mental health. vol 21. issue 3. 2019-05-17. PMID:29997153. |
clozapine and long-acting injectable antipsychotics reduce hospitalisation and treatment failure risk in patients with schizophrenia. |
2019-05-17 |
2023-08-13 |
Not clear |
| Dalia Ismail, Karawen Tounsi, Monica Zolezzi, Yassin Eltork. A qualitative exploration of clozapine prescribing and monitoring practices in the Arabian Gulf countries. Asian journal of psychiatry. vol 39. 2019-05-08. PMID:30597443. |
clozapine is considered as the first line antipsychotic for treatment resistant schizophrenia (trs). |
2019-05-08 |
2023-08-13 |
human |
| Jan P A M Bogers, Peter F J Schulte, Theo G Broekman, Peter Moleman, Lieuwe de Haa. Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: A 1-year double-blind randomized clinical trial. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 28. issue 9. 2019-05-03. PMID:30025751. |
neither fga dose reduction nor switching to ziprasidone is an adequate alternative to clozapine for long-stay patients with severe treatment resistant schizophrenia. |
2019-05-03 |
2023-08-13 |
Not clear |
| Vincenzo Prisco, Petrosino Monica, Germano Fiore, Annamaria Tridente, Antonietta La Rocca, Francesco Catapano, Michele Fabrazz. Brain Natriuretic Peptide as a Biomarker of Asymptomatic Clozapine-Related Heart Dysfunction: A Criterion for a More Cautious Administration. Clinical schizophrenia & related psychoses. vol 12. issue 4. 2019-04-29. PMID:27996318. |
we reported the clinical cases of two women, aged 22 and 28 years, affected by schizophrenia with pericarditis symptoms related to clozapine treatment of 200 mg/day. |
2019-04-29 |
2023-08-13 |
human |
| Katlyn L Nemani, M Claire Greene, Melissa Ulloa, Brenda Vincenzi, Paul M Copeland, Sulaiman Al-Khadari, David C Henderso. Clozapine, Diabetes Mellitus, Cardiovascular Risk and Mortality: Results of a 21-Year Naturalistic Study in Patients with Schizophrenia and Schizoaffective Disorder. Clinical schizophrenia & related psychoses. vol 12. issue 4. 2019-04-29. PMID:29164928. |
clozapine, diabetes mellitus, cardiovascular risk and mortality: results of a 21-year naturalistic study in patients with schizophrenia and schizoaffective disorder. |
2019-04-29 |
2023-08-13 |
Not clear |
| Radhika Sudhir Joshi, Shishu Pal Singh, Mitradas M Panicke. 5-HT Journal of pharmacological sciences. vol 139. issue 2. 2019-04-17. PMID:30600145. |
5-ht clozapine is an antipsychotic known for its superior efficacy in treating drug-resistant schizophrenia. |
2019-04-17 |
2023-08-13 |
Not clear |
| Takayuki Furuishi, Kohei Sekino, Mihoko Gunji, Kaori Fukuzawa, Hiromasa Nagase, Tomohiro Endo, Haruhisa Ueda, Etsuo Yonemoch. Effect of sulfobutyl ether-β-cyclodextrin and propylene glycol alginate on the solubility of clozapine. Pharmaceutical development and technology. vol 24. issue 4. 2019-04-15. PMID:30126299. |
clozapine (clz) is an atypical antipsychotic medication used in the treatment of schizophrenia and is poorly soluble in water (0.05 mm). |
2019-04-15 |
2023-08-13 |
Not clear |
| Lisanne M Geers, Dan Cohen, Laura M Wehkamp, Kai van Hateren, Remco A Koster, Olga Yu Fedorenko, Arkadyi V Semke, Nikolay Bokhan, Svetlana A Ivanova, Jos G W Kosterink, Anton J M Loonen, Daan J Tou. Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Clozapine. The Journal of clinical psychiatry. vol 78. issue 9. 2019-04-03. PMID:29068609. |
clozapine is an antipsychotic drug that is mainly used in the treatment of schizophrenia patients who are refractory or intolerant to at least 2 other antipsychotics. |
2019-04-03 |
2023-08-13 |
Not clear |